BR112014010204A2 - composto, métodos para tratar aterosclerose, para aumentar o hdl-c, para reduzir p ldl-c e para tratar dislipidemia em um paciente, e, uso do composto, composição fermacêutica - Google Patents

composto, métodos para tratar aterosclerose, para aumentar o hdl-c, para reduzir p ldl-c e para tratar dislipidemia em um paciente, e, uso do composto, composição fermacêutica

Info

Publication number
BR112014010204A2
BR112014010204A2 BR112014010204A BR112014010204A BR112014010204A2 BR 112014010204 A2 BR112014010204 A2 BR 112014010204A2 BR 112014010204 A BR112014010204 A BR 112014010204A BR 112014010204 A BR112014010204 A BR 112014010204A BR 112014010204 A2 BR112014010204 A2 BR 112014010204A2
Authority
BR
Brazil
Prior art keywords
compound
treating
ldl
patient
reducing
Prior art date
Application number
BR112014010204A
Other languages
English (en)
Portuguese (pt)
Inventor
Sha Deyou
Ye Feng
Liu Jian
Patrick Shao Pengcheng
Vachal Petr
Reddy Katipally Revathi
Sun Wanying
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112014010204A2 publication Critical patent/BR112014010204A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112014010204A 2011-10-28 2012-10-25 composto, métodos para tratar aterosclerose, para aumentar o hdl-c, para reduzir p ldl-c e para tratar dislipidemia em um paciente, e, uso do composto, composição fermacêutica BR112014010204A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552592P 2011-10-28 2011-10-28
PCT/US2012/061842 WO2013063217A1 (en) 2011-10-28 2012-10-25 Fused bicyclic oxazolidinone cetp inhibitor

Publications (1)

Publication Number Publication Date
BR112014010204A2 true BR112014010204A2 (pt) 2017-05-09

Family

ID=47143312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010204A BR112014010204A2 (pt) 2011-10-28 2012-10-25 composto, métodos para tratar aterosclerose, para aumentar o hdl-c, para reduzir p ldl-c e para tratar dislipidemia em um paciente, e, uso do composto, composição fermacêutica

Country Status (41)

Country Link
US (2) US8871738B2 (cg-RX-API-DMAC7.html)
EP (1) EP2771345B1 (cg-RX-API-DMAC7.html)
JP (1) JP5658427B2 (cg-RX-API-DMAC7.html)
KR (1) KR101686308B1 (cg-RX-API-DMAC7.html)
CN (1) CN103958524B (cg-RX-API-DMAC7.html)
AR (1) AR088565A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012328759B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010204A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852743C (cg-RX-API-DMAC7.html)
CL (1) CL2014001090A1 (cg-RX-API-DMAC7.html)
CO (1) CO6940419A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140256A (cg-RX-API-DMAC7.html)
CY (1) CY1118464T1 (cg-RX-API-DMAC7.html)
DK (1) DK2771345T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000086A (cg-RX-API-DMAC7.html)
EA (1) EA026123B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14002458A (cg-RX-API-DMAC7.html)
ES (1) ES2604953T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166434B (cg-RX-API-DMAC7.html)
HR (1) HRP20161541T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030568T2 (cg-RX-API-DMAC7.html)
IL (1) IL232130A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03073A (cg-RX-API-DMAC7.html)
JO (1) JO3210B1 (cg-RX-API-DMAC7.html)
LT (1) LT2771345T (cg-RX-API-DMAC7.html)
MA (1) MA35643B1 (cg-RX-API-DMAC7.html)
ME (1) ME02557B (cg-RX-API-DMAC7.html)
MX (1) MX345222B (cg-RX-API-DMAC7.html)
NI (1) NI201400034A (cg-RX-API-DMAC7.html)
PE (1) PE20141230A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500890A1 (cg-RX-API-DMAC7.html)
PL (1) PL2771345T3 (cg-RX-API-DMAC7.html)
PT (1) PT2771345T (cg-RX-API-DMAC7.html)
RS (1) RS55420B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401884PA (cg-RX-API-DMAC7.html)
SI (1) SI2771345T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000158A1 (cg-RX-API-DMAC7.html)
TW (1) TWI601731B (cg-RX-API-DMAC7.html)
UA (1) UA114612C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013063217A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201403091B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
JP5852662B2 (ja) 2010-10-29 2016-02-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 環状アミン置換されたオキサゾリジノン系ｃｅｔｐ阻害薬
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2934518B1 (en) 2012-12-19 2020-02-19 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
US9376408B2 (en) 2012-12-20 2016-06-28 Merck Sharp & Dohme Corp. Therapeutic thiazolidinone compounds
DK2943474T3 (en) * 2013-01-31 2017-08-21 Chong Kun Dang Pharmaceutical Corp BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXE DERIVATE COMPOUNDS AS CETP INHIBITORS
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3027619B1 (en) * 2013-07-30 2019-01-02 Merck Sharp & Dohme Corp. Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
WO2015031228A1 (en) * 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
US9663534B2 (en) 2013-12-17 2017-05-30 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
UA120922C2 (uk) 2014-02-05 2020-03-10 Дезима Фарма Б.В. Інгібітор білка-переносника ефіру холестерину (cetp) і фармацевтичні композиції, які містять вказаний інгібітор, для застосування в лікуванні або запобіганні серцево-судинним захворюванням
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HRP20210338T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije fgfr-i cmet-inhibitora za liječenje raka
CN106456648B (zh) 2014-03-26 2021-11-02 阿斯特克斯治疗有限公司 Fgfr抑制剂和igf1r抑制剂的组合
US10011572B2 (en) 2014-07-29 2018-07-03 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016067194A1 (en) * 2014-10-27 2016-05-06 Sun Pharmaceutical Industries Limited Process for the preparation of anacetrapib and an intermediate thereof
US20170252338A1 (en) * 2014-11-28 2017-09-07 Kowa Company, Ltd. Medicine
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN109996757A (zh) * 2015-06-12 2019-07-09 罗地亚经营管理公司 含枝状体的混合纳米粒子、生产此类混合纳米粒子的方法以及它们的用途
US20180230166A1 (en) * 2015-07-13 2018-08-16 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
LT3353164T (lt) 2015-09-23 2022-01-25 Janssen Pharmaceutica, N.V. Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui
AU2016328692B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv New compounds
CN106432053A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法
CN106432058A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种Niraparib中间体4‑（3S‑哌啶‑3‑基）苯胺的制备方法
CN111285894B (zh) * 2018-12-10 2021-03-05 北京天一绿甫医药科技有限公司 用于制备软海绵素类化合物的中间体及其制备方法
CN110639018B (zh) * 2019-11-14 2020-06-26 牡丹江医学院 一种防治老年性高血压的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc INDOLES HAVING ANTIDIABETIC EFFECT
PT1537078E (pt) 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
CN100403900C (zh) * 2003-06-12 2008-07-23 麦克公司 有丝分裂驱动蛋白抑制剂
US7307085B2 (en) 2003-08-13 2007-12-11 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1938320A (zh) * 2004-03-26 2007-03-28 伊莱利利公司 用于治疗异常脂肪血症的化合物和方法
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US7888369B2 (en) 2005-12-22 2011-02-15 Schering Corporation Oxazoloisoquinoline derivatives as thrombin receptor antagonists
US7910592B2 (en) 2005-12-30 2011-03-22 Merck Sharp & Dohme Corp. CETP inhibitors
AU2006335110B2 (en) 2005-12-30 2011-04-14 Merck Sharp & Dohme Corp. CETP inhibitors
EP2029560B1 (en) 2005-12-30 2013-04-24 Merck Sharp & Dohme Corp. 1,3-oxazolidin-2-one derivatives useeful as cetp inhibitors
EP2348859B1 (en) 2008-10-01 2013-12-04 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone cetp inhibitors
WO2011028395A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Pyridyl oxazolidinone cetp inhibitor
JP5852662B2 (ja) 2010-10-29 2016-02-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 環状アミン置換されたオキサゾリジノン系ｃｅｔｐ阻害薬
US9353101B2 (en) 2012-05-02 2016-05-31 Merck Sharp & Dohme Corp. Cyclic amine substituted heterocyclic CETP inhibitors

Also Published As

Publication number Publication date
PH12014500890A1 (en) 2014-06-09
PE20141230A1 (es) 2014-09-28
US9346825B2 (en) 2016-05-24
CN103958524A (zh) 2014-07-30
ECSP14002458A (es) 2015-11-30
MX345222B (es) 2017-01-20
NI201400034A (es) 2014-10-10
US20140378493A1 (en) 2014-12-25
LT2771345T (lt) 2016-11-25
AU2012328759A1 (en) 2014-05-01
GEP20166434B (en) 2016-02-10
TW201321388A (zh) 2013-06-01
JP2014532652A (ja) 2014-12-08
AR088565A1 (es) 2014-06-18
ES2604953T3 (es) 2017-03-10
PL2771345T3 (pl) 2017-04-28
RS55420B1 (sr) 2017-04-28
IN2014CN03073A (cg-RX-API-DMAC7.html) 2015-07-31
ME02557B (me) 2017-02-20
EP2771345B1 (en) 2016-09-21
DK2771345T3 (en) 2017-01-09
ZA201406833B (en) 2016-02-24
HRP20161541T1 (hr) 2016-12-30
MX2014005074A (es) 2014-08-01
NZ625435A (en) 2015-12-24
SG11201401884PA (en) 2014-09-26
TN2014000158A1 (en) 2015-09-30
PT2771345T (pt) 2016-11-30
DOP2014000086A (es) 2014-07-15
AU2012328759B2 (en) 2015-09-10
CA2852743A1 (en) 2013-05-02
EA026123B1 (ru) 2017-03-31
CR20140256A (es) 2014-07-15
EA201490889A1 (ru) 2015-05-29
US20130109649A1 (en) 2013-05-02
UA114612C2 (uk) 2017-07-10
ZA201403091B (en) 2015-04-29
KR101686308B1 (ko) 2016-12-13
CN103958524B (zh) 2016-04-06
IL232130A0 (en) 2014-05-28
CO6940419A2 (es) 2014-05-09
US8871738B2 (en) 2014-10-28
KR20140094571A (ko) 2014-07-30
IL232130A (en) 2017-07-31
MA35643B1 (fr) 2014-11-01
CL2014001090A1 (es) 2014-08-01
WO2013063217A1 (en) 2013-05-02
SI2771345T1 (sl) 2016-12-30
EP2771345A1 (en) 2014-09-03
CA2852743C (en) 2016-08-02
HUE030568T2 (en) 2017-05-29
CY1118464T1 (el) 2017-07-12
TWI601731B (zh) 2017-10-11
JO3210B1 (ar) 2018-03-08
HK1195558A1 (zh) 2014-11-14
JP5658427B2 (ja) 2015-01-28

Similar Documents

Publication Publication Date Title
BR112014010204A2 (pt) composto, métodos para tratar aterosclerose, para aumentar o hdl-c, para reduzir p ldl-c e para tratar dislipidemia em um paciente, e, uso do composto, composição fermacêutica
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015004547A2 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BR112014009686A2 (pt) composição analgésica inalável, pó seco e método para tratar dor
BR112015004489A2 (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112013031819A2 (pt) suporte polimérico, composição farmacêutica, composto, métodos de tratar um distúrbio, e, de preparar um suporte
PT2739268T (pt) Método e formulação para inalação
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014006420A2 (pt) compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
CO7000752A2 (es) Sistemas y métodos para rotores hidráulicos mejorados
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
HRP20170928T1 (hr) Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
BR112013018679A2 (pt) agente para o tratamento da alopecia
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BR112012020585A2 (pt) composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio
BR112015003698A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método para o tratamento de câncer
IL233644A0 (en) Formulation of doxylamine and pyridoxine and/or their metabolites or salts
BR112014008241A2 (pt) composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]